Clarity advances to cohort 2 in the SARTATE™ neuroblastoma trial
Sydney, Australia 1 February 2022 Cohort 1 completed in 3 participants with neuroblastoma who received therapy with 67Cu SARTATE™ at a dose of 75MBq/kg body weight No dose limiting toxicities (DLTs) have been reported in cohort 1 The Safety Review Committee (SRC) has recommended the trial continues with the dose escalation phase as planned Recruitment…